

# **Cataract surgery in HIV+ patients**

Accorinti M., Cecere M., Scala A., Pirraglia M.P. Dipartimento Organi di Senso, Sapienza Università di Roma, Rome - Italy Financial interests: none



Purpose: to study the epidemiologic and clinical findings of cataract and the long-term results of cataract surgery in HIV+ patients

Patients & Methods: data from 32 HIV+ patients, 22 males (68.7%),11 with uveitis or retinitis before surgery and 21 without, with a mean post-op follow-up of 44.9 + 36.6 months, and those from 114 HIV- patients, 57 with uveitis or retinitis (24 males, 42.1%) with a mean postop follow-up of 50.1 + 37.7 months and 57 without (21 males, 36.8%) with a mean post-op follow-up of 46.4 + 15.2 months, were compared.


#### **Results: Epidemiology and clinical findings of HIV+** patients with and without uveitis prior to cataract surgery

Patients with uveitis Patients without uveitis р before surgery before surgery N° (%) N° (%) N° patients 11/32 21/32 11/36 25/36 N° eyes 0.027 Males 6 /11(54.5%) 16/21 (76.19%) Females 5/11 (45.4%) 5 /21 (23.8%) 58 <u>+</u> 11.75 (37-74) 0.01 Mean age at surgery 46.73 <u>+</u> 9.5 (33-63) (yrs) **Bilateral cataract** 4 (19.04%) 0.32 6 (24%) 0.19 Nuclear cataract (N) 1 (4%) 0.67 **Cortical cataract (C)** 

Intraoperative and postoperative complications and intraoperative manoeuvres in HIV+ patients with and without uveitis prior to surgery

|                                  | Patients<br>with<br>uveitis | Patients<br>without<br>uveitis | р     |
|----------------------------------|-----------------------------|--------------------------------|-------|
|                                  | N° eyes<br>(%)              | N° eyes<br>(%)                 |       |
| Phaco+ IOL implantation          | 11                          | <u> </u>                       |       |
| Intraoperative complications     | 0                           | 0                              |       |
| Intraoperative manoeuvres        |                             |                                |       |
| - iris hook                      | 2 (18.2)                    | 0                              | 0.16  |
| - trypan blu                     | 1 (9.1)                     | 0                              | 0.67  |
| - synechiotomy                   | 3 (27.3)                    | 0                              | 0.038 |
| - iridectomy                     | 1 (9.1)                     | 0                              | 0.67  |
| - epilenticular membrane removal | 1 (9.1)                     | 0                              | 0.67  |
| Postoperative complications      | 5 (45.4)                    | 4 (16)                         | 0.144 |
| - cystoid macular edema          | 1 (9.1)                     | 0                              | 0.67  |
| - pupil margin rupture           | 2 (18.2)                    | 0                              | 0.16  |
| - IOL dislocation                | 1 (9.1)                     | 0                              | 0.67  |
| - macular pucker                 | 0                           | 1(4)                           | 0.67  |
| - descemet's folds at 1wk        | 2 (18.2)                    | 1 (4)                          | 0.45  |
| - posterior capsule opacity      | 2 (18.2)                    | 2 (8)                          | 0.75  |
| - Nd:YAG laser capsulotomy       | 1 (9.1)                     | 1 (4)                          | 0.86  |


Mean BCVA, flare and cells in anterior chamber at baseline and during follow-up after cataract surgery in all HIV+ patients



| Posterior subcapsular<br>cataract (PSC) | 4 (36.36%) | 2 (8%)      | 0.11 |
|---|------------|-------------|------|
| N+C cataract                            | 0          | 8 (32%)     | 0.09 |
| C+S cataract                            | 1 (9.1%)   | 0           | 0.67 |
| N+PSC cataract                          | 4 (36.36%) | 2 (8%)      | 0.11 |
| N+C+PSC cataract                        | 1 (9.1%)   | 4 (16%)     | 0.98 |
| Total cataract                          | 1 (9.1%)   | 2 (8%)      | 0.58 |
| Co-morbidities*                         | 5 (45.45%) | 17 (80.95%) | 0.09 |

\*Co-morbidities including diabetes, hypertension, dyslipidaemia, HBV and HCV infection, TB, zoster infection, pancreatitis, heart lesions, chronic renal failure, thyroid changes, lymphoma, pulmonary lesions and gastrointestinal lesions were equally distributed among groups

### Mean BCVA




## Epidemiology and clinical findings of HIV+ and **HIV- patients with uveitis prior to cataract surgery**

| HIV + patients | HIV- patients | р |
|----------------|---------------|---|
| N (%)          | N (%)         |   |

| 0.2          |   |                    |         |         |         |                     |  |  |  |  |  |
|--------------|---|--------------------|---------|---------|---------|---------------------|--|--|--|--|--|
| 0.1          | Reconcered to a second to a |                    |         |         |         |                     |  |  |  |  |  |
| 0            | baseline  | 1 week post-<br>op | 1 month | 3 month | 6 month | last<br>examination |  |  |  |  |  |
| mean BCVA    | 0.45  | 0.83               | 0.83    | 0.85    | 0.85    | 0.82                |  |  |  |  |  |
| - mean flare | 0.01  | 0.06               | 0.04    | 0.03    | 0.06    | 0.01                |  |  |  |  |  |
| - mean cells | 0   | 0.07               | 0.04    | 0.01    | 0.07    | 0                   |  |  |  |  |  |

0.25

\*cells increased significantly at day 7 thereafter returning to baseline values during the follow-up flare did not change significantly from baseline



\*IOL in the sulcus

| act surgery       0.16         0.14       0.12         0.1       0.1         nts with       0.08         0.04       0.04 |                      |                         |                             |                             |                             | changes after <sup>0.2</sup><br>cataract surgery <sup>0.15</sup><br>in HIV+ patients <sup>0.1</sup><br>with and without <sup>05</sup> |  |
|--|----------------------|-------------------------|-----------------------------|-----------------------------|-----------------------------|---|--|
| without 0.04<br>0.02<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0<br>0                | flare pre<br>p=0.098 | flare 1 week<br>p<0.001 | flare 1<br>month<br>p=0.004 | flare 3<br>month<br>p=0.028 | flare 6<br>month<br>p=0.011 | <ul> <li>with and without</li> <li>uveitis prior to</li> <li>cataract surgery</li> </ul>  |  |
| → Patients with ocular inflammation  | 0.05                 | 0.18                    | 0.14                        | 0.09                        | 0.18                        | ── Patients with ocular inflammation  |  |
| <ul> <li>F Patients without ocular<br/>inflammation</li> </ul>   | 0                    | 0                       | 0                           | 0                           | 0                           | - G- Patients without ocular<br>inflammation  |  |

Mean cells

| ges alter                             |           |              |         |         |         |             |  |
|---------------------------------------|-----------|--------------|---------|---------|---------|-------------|--|
| act surgery <sup>115</sup>            |           | /            | A       | /       |         |             |  |
| V+ patients 0.1                       | /         | /            |         |         |         |             |  |
| and without <sup>05</sup>             |           |              |         |         |         |             |  |
| is prior to 0                         | cells pre | cells 1 week | cells 1 | cells 3 | cells 6 | cells last  |  |
| act surgery                           |           |              | month   | month   | month   | examination |  |
|                                       | p=1       | p<0.001      | p=0.032 | p=0.098 | p=0.007 | p=1         |  |
| tients with ocular inflammation       | 0         | 0.23         | 0.14    | 0.05    | 0.23    | 0           |  |
| tients without ocular<br>inflammation | 0         | 0            | 0       | 0       | 0       | 0           |  |
|                                       |           |              |         |         |         |             |  |

Intra-and post-operative complications and intraoperative manoeuvres in HIV+ and HIV-

0.2

0.18


patients with uveitis prior to cataract surgery


| patients with uverus pric                   |          | ιαιατί σι | n ger |
|---|----------|-----------|-------|
|   | HIV +    | HIV-      | р     |
|   | patients | patients  |       |
|   | N° eyes  | N° eyes   |       |
|   | (%)      | (%)       |       |
| Phaco+ IOL implantation                     | 11       | 73        |       |
| Intraoperative complications                | 0 (0)    | 1 (1.36)* | 0.271 |
| Intraoperative manoeuvres                   |          |           |       |
| - iris hook                                 | 2 (18.2) | 26 (35.6) | 0.423 |
| - trypan blu                                | 1 (9.1   | 21 (28.7) | 0.31  |
| - synechiotomy                              | 3 (27.3) | 34 (46.6) | 0.381 |
| - iridectomy                                | 1 (9.1)  | 1 (1.4)   | 0.613 |
| - epilenticular membrane removal            | 1 (9.1)  | 1 (1.4)   | 0.613 |
| Postoperative complications                 |          |           |       |
| - cystoid macular edema                     | 1 (9.1)  | 9 (12.3)  | 0.849 |
| - pupil margin rupture                      | 2 (18.2  | 26 (35.6) | 0.423 |
| - IOL dislocation                           | 1 (9.1)  | 0         | 0.271 |
| - macular pucker                            | 0        | 0         | 1     |
| <ul> <li>descemet's folds at 1wk</li> </ul> | 3 (27.3) | 8 (10.9)  | 0.31  |
| - posterior capsule opac.                   | 2 (18.2) | 19 (26)   | 0.852 |
| - Nd:YAG laser capsulotomy                  | 1 (9.1)  | 13 (17.8) | 0.772 |
|   |          |           |       |

### Mean BCVA changes after cataract surgery in HIV+ and **HIV- patients with uveitis prior to cataract surgery**

| N° patients               | 32                         | 57                       |       |
|---------------------------|----------------------------|--------------------------|-------|
| N° eyes                   | 36                         | 73                       |       |
| Male                      | 22 (68.75)                 | 24 (42.1)                | 0.028 |
| Female                    | 10 (31.25)                 | 33 (57.9)                |       |
| Mean age (yrs)            | 54.1 <u>+</u> 12.1 (33-74) | 51. <u>+</u> 18.8 (9-82) | 0.41  |
|                           |                            |                          |       |
| <b>Bilateral cataract</b> | 4 (12.5)                   | 15 (26.3)                | 0.209 |
| Nuclear cataract          | 6 (16.6)                   | 4 (5.47)                 | 0.121 |
| <b>Cortical cataract</b>  | 1 (2.7)                    | 0 (0)                    | 0.717 |
| Posterior                 | 6 (16.6)                   | 15 (20.5)                | 0.822 |
| subcapsular cataract      |                            |                          |       |
| N+C cataract              | 8 (22.2)                   | 16 (21.9)                | 0.95  |
| C+S cataract              | 1 (2.7)                    | 12 (16.4)                | 0.079 |
| N+S cataract              | 6 (16.6)                   | 14 (19.2)                | 0.956 |
| N+C+S cataract            | 5 (13.8)                   | 8 (10.9)                 | 0.897 |
| Total cataract            | 3 (8.3)                    | 4 (5.5)                  | 0.876 |
|                           |                            |                          |       |
| <b>Co-morbidities*</b>    | 22 (68.7)                  | 32 (56.1)                | 0.346 |
| Diabetes                  | 8 (25)                     | 4 (7)                    | 0.039 |
| Dyslipidaemia             | 13 (40.6)                  | 10 (17.5)                | 0.033 |
|                           |                            |                          |       |

\*All the other co-morbidities were equally distributed among groups





**Comparison between HIV+ and HIV- patients** without uveitis prior to cataract surgery (25 and 93 eyes, respectively) No significant intraoperative or post-operative complications Same significant increase of BCVA after surgery (p<0.001) HIV + patients showed: 1) male prevalence (76% vs 36%) p= 0.005 2) younger age at surgery (58 vs 69.4 years) p<0.001 3) unilateral cataract (81% vs 36.9%) p=0.001 4) more frequently total cataract (8% vs 0) p=0.06 5) less frequently nuclear + cortical cataract (32% vs 57%) p=0.046 6) more frequently dislypidaemia (52.4% vs 26.3%) p=0.058 7) more frequently HBV infection (9.5% vs 0%) p=0.037

|                     | flare pre | flare 1 week | flare 1<br>month | flare 3<br>month | flare 6<br>month | flare final<br>examination | cell pre | cells 1 week | cells 1 moth | cells 3<br>month | cells 6<br>month | cells final<br>examination |
|---------------------|-----------|--------------|------------------|------------------|------------------|----------------------------|----------|--------------|--------------|------------------|------------------|----------------------------|
| - < - Patients HIV+ | 0.05      | 0.18         | 0.14             | 0.09             | 0.18             | 0.05                       | 0        | 0.23         | 0.14         | 0.05             | 0.23             | 0                          |
|                     | 0.29      | 0.54         | 0.29             | 0.29             | 0.29             | 0.23                       | 0.025    | 0.55         | 0.2          | 0.21             | 0.21             | 0.17                       |

**Comments:** HIV+ patients present senile cataract earlier than HIV- subjects and have more associated systemic co-morbidities. Cataract is more frequently found in males, is unilateral, with little differences as concern the type of lens opacity. HIV+ patients with a diagnosis of uveitis/retinitis before cataract surgery: - are more frequently males and younger than those without uveitis; - have a significant, but lower, increase in BCVA at the end of follow-up; - need more sinechiotomy; - have more inflammation in anterior chamber up to six months, but without differences at the end of follow-up. The course of inflammation in patients with uveitis before surgery is similar in HIV+ and HIV- patients, although HIV- patients present fewer systemic co-morbidities and higher final BCVA. No difference can be found in post-op inflammation and final BCVA in HIV+ and HIV- patients without uveitis/retinitis before surgery.

**Conclusions:** although HIV+ patients present more associated systemic diseases than HIV- ones, cataract surgery in those patients is safe and useful, independently from the presence of uveitis/retinitis before surgery. Cataract surgery in HIV+ patients allows a significant increase in BCVA, especially in those patients without uveitis/retinitis prior to surgery who are free from preexisting macular and optic nerve damage.